Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy for
treating multiple refractory blood cancers, but further advances are required for solid tumor …

Chimeric antigen receptor T cell (CAR-T) therapy to hematological malignancies has
demonstrated tremendous clinical outcomes. However, the therapeutic efficacy of CAR-T …

Adoptive immunotherapy leveraging chimeric antigen receptor-modified T (CAR-T) cells
holds great promise for the treatment of cancer. However, tumor-associated antigens often …

The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs)
has shown remarkable curative potential against advanced B-cell malignancies, but multiple …

The limited number of targetable tumor-specific antigens and the immunosuppressive nature
of the microenvironment within solid malignancies represent major barriers to the success of …

Targeted T cells are emerging as effective non-toxic therapies for cancer. Multiple elements,
however, contribute to the overall pathogenesis of cancer through both distinct and …

Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated
antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a …

Options for targeted therapy of T-cell malignancies remain scarce. Recent clinical trials
demonstrated that chimeric antigen receptors (CARs) can effectively redirect T lymphocytes …

Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have performed
poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated …

Chimeric antigen receptors (CARs) combine T cell activation with antibody-mediated tumor
antigen specificity, bypassing the need for T cell receptor (TCR) ligation. A limitation of CAR …